Quantum BioPharma to conduct Phase 2 trial

Quantum BioPharma has signed a binding letter of intent with Allucent to conduct a Phase 2 clinical trial for its multiple sclerosis treatment, Lucid-21-302 (Lucid-MS). This collaboration with a global Clinical Research Organization (CRO) marks a significant step forward in the drug's development. The trial aims to further evaluate the efficacy and safety of Lucid-MS in patients with multiple sclerosis. Successful completion of this phase could pave the way for further clinical development and potential regulatory approval. The partnership signifies progress in addressing unmet medical needs.